个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共38条记录   Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer [作者：Le, QT; Fisher, R; Oliner, KS; Young, RJ; Cao, HC; Kong, C; Graves, E; Hicks, RJ; McArthur, GA; Peters, L; O'Sullivan, B; Giaccia, A; Rischin, D,期刊：Clinical Cancer Research, 页码：1798-1807 , 文章类型： Article，,卷期：2012年18-6] Purpose: Hepatocyte growth factor (HGF) is a hypoxia-induced secreted protein that binds to cMet and regulates interleukin (IL)-8 expression. We evaluated the role of circulating HGF and IL-8 as prognostic and predictive... IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors [作者：Becker, MA; Hou, XN; Harrington, SC; Weroha, SJ; Gonzalez, SE; Jacob, KA; Carboni, JM; Gottardis, MM; Haluska, P,期刊：Clinical Cancer Research, 页码：1808-1817 , 文章类型： Article，,卷期：2012年18-6] Purpose: To improve the significance of insulin-like growth factor-binding protein 5 (IGFBP-5) as a prognostic and potentially predictive marker in patients with breast cancer. Experimental Design: Increased IGFBP-5 expr... Imaging Tumor Sensitivity to a Bioreductive Prodrug: Two for the Price of One! [作者：Brown, JM,期刊：Clinical Cancer Research, 页码：1487-1489 , 文章类型： Editorial Material，,卷期：2012年18-6] Hypoxia is an important characteristic of many solid tumors and has a major negative effect on treatment response. A way to combat this effect is with drugs called "bioreductive prodrugs" or "hypoxic cytotoxins," which a... Two Sides of the Same Coin: EGFR Exon 19 Deletions and Insertions in Lung Cancer [作者：Politi, K; Lynch, TJ,期刊：Clinical Cancer Research, 页码：1490-1492 , 文章类型： Editorial Material，,卷期：2012年18-6] Most lung adenocarcinoma-associated EGF receptor (EGFR) mutations confer sensitivity to specific EGFR tyrosine kinase inhibitors. The finding that exon 19 insertion mutations are also sensitive to this class of drugs sug... Phospho-specific Flow: Fixating on the Target [作者：Levis, M,期刊：Clinical Cancer Research, 页码：1493-1495 , 文章类型： Editorial Material，,卷期：2012年18-6] Targeted therapies are all the rage in oncology research these days. The problem remains as to how to confirm that the target is actually being hit in vivo. This report describes the application of phospho-specific flow ... Eribulin Mesylate for the Treatment of Patients with Refractory Metastatic Breast Cancer: Use of a "Physician's Choice" Control Arm in a Randomized Approval Trial [作者：Donoghue, M; Lemery, SJ; Yuan, WS; He, K; Sridhara, R; Shord, S; Zhao, H; Marathe, A; Kotch, L; Jee, J; Wang, Y; Zhou, L; Adams, WM; Jarral, V; Pilaro, A; Lostritto, R; Gootenberg, JE; Keegan, P; Pazdur, R,期刊：Clinical Cancer Research, 页码：1496-1505 , 文章类型： Article，,卷期：2012年18-6] This work describes the considerations that led to the approval by the U. S. Food and Drug Administration (FDA), on November 15, 2010, of eribulin mesylate (Halaven; Eisai, Inc.) for the treatment of patients with refrac... Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive, and Therapeutic Implications [作者：Sinicrope, FA; Sargent, DJ,期刊：Clinical Cancer Research, 页码：1506-1512 , 文章类型： Article，,卷期：2012年18-6] Microsatellite instability (MSI) is the molecular fingerprint of the deficient mismatch repair (MMR) system, which characterizes similar to 15% of colorectal cancers. MSI develops as a result of germline mutations in MMR... Molecular Diagnostics: Are We There Yet? [作者：Bates, SE,期刊：Clinical Cancer Research, 页码：1514-1514 , 文章类型： Editorial Material，,卷期：2012年18-6] Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development [作者：Poste, G; Carbone, DP; Parkinson, DR; Verweij, J; Hewitt, SM; Jessup, JM,期刊：Clinical Cancer Research, 页码：1515-1523 , 文章类型： Article，,卷期：2012年18-6] Molecular diagnostics are becoming increasingly important in clinical research to stratify or identify molecularly profiled patient cohorts for targeted therapies, to modify the dose of a therapeutic, and to assess early... Impact of Preanalytic Factors on the Design and Application of Integral Biomarkers for Directing Patient Therapy [作者：Hewitt, SM; Badve, SS; True, LD,期刊：Clinical Cancer Research, 页码：1524-1530 , 文章类型： Article，,卷期：2012年18-6] Molecular assays have been routinely applied to improve diagnosis for the last 25 years. Assays that guide therapy have a similar history; however, their evolution has lacked the focus on analytic integrity that is requi... Bridging the Gap: Moving Predictive and Prognostic Assays from Research to Clinical Use [作者：Williams, PM; Lively, TG; Jessup, JM; Conley, BA,期刊：Clinical Cancer Research, 页码：1531-1539 , 文章类型： Article，,卷期：2012年18-6] The development of clinically useful molecular diagnostics requires validation of clinical assay performance and achievement of clinical qualification in clinical trials. As discussed elsewhere in this Focus section on m... Development and Use of Integral Assays in Clinical Trials [作者：Schilsky, RL; Doroshow, JH; LeBlanc, M; Conley, BA,期刊：Clinical Cancer Research, 页码：1540-1546 , 文章类型： Article，,卷期：2012年18-6] Clinical trials that include integral biomarkers to determine eligibility, assign treatment, or assess outcome must employ robust assays to measure the molecular analyte of interest. The decision to develop a biomarker a... Lessons Learned from the Investigational Device Exemption Review of Children's Oncology Group Trial AAML1031 [作者：Meshinchi, S; Hunger, SP; Aplenc, R; Adamson, PC; Jessup, JM,期刊：Clinical Cancer Research, 页码：1547-1554 , 文章类型： Review，,卷期：2012年18-6] The U.S. Food and Drug Administration is now exerting its regulatory authority over the use of molecular diagnostics and related assays for medical decision making in clinical trials, by performing pre-Investigational De... Biomarker Discovery, Development, and Implementation in France: A Report from the French National Cancer Institute and Cooperative Groups [作者：Andre, F; Nowak, F; Arnedos, M; Lacroix, L; Viens, P; Calvo, F,期刊：Clinical Cancer Research, 页码：1555-1560 , 文章类型： Article，,卷期：2012年18-6] Biomarkers are increasingly changing the medical practice in oncology. One of the major challenges in the field of personalized medicine or biologically adapted therapies is to ensure a rapid and extensive implementation... The Fundamental Role of the p53 Pathway in Tumor Metabolism and Its Implication in Tumor Therapy [作者：Shen, L; Sun, X; Fu, ZH; Yang, GD; Li, JY; Yao, LB,期刊：Clinical Cancer Research, 页码：1561-1567 , 文章类型： Review，,卷期：2012年18-6] It is well established that the altered metabolism exhibited by cancer cells, including high rates of glycolysis, lactate production, and biosynthesis of lipids, nucleotides, and other macromolecules, and which may occur... Expression of Interleukin-4 Receptor Alpha in Human Pleural Mesothelioma Is Associated with Poor Survival and Promotion of Tumor Inflammation [作者：Burt, BM; Bader, A; Winter, D; Rodig, SJ; Bueno, R; Sugarbaker, DJ,期刊：Clinical Cancer Research, 页码：1568-1577 , 文章类型： Article，,卷期：2012年18-6] Purpose: The origin and pathogenesis of malignant pleural mesothelioma (MPM) are closely aligned with inflammation. MPM tumors express interleukin-4 receptor a (IL-4R alpha), the principal subunit of the IL-4 receptor. W...